BioSpace News Archive

The annual general meeting was held in AlzeCure Pharma AB.

A new study adds to an emerging, radically new picture of how bacterial cells continually repair faulty sections of their DNA.

Bausch Health Companies Inc. (NYSE/TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. District Court of Delaware in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc., has denied Norwich Pharmaceuticals’ motion to modify the Court’s final judgment that prevents the U.S. Food and Drug Administration (FDA) from approving Norwich’s abbreviated new drug application (ANDA) for XIFAXAN® (rifaximin) 550 mg before Oct. 2, 2029.

New funding led by ICONIQ Growth brings total raised to $207 million and signals investor confidence in Apprentice’s market-leading technology

AB Science SA (Euronext – FR0010557264 – AB) today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, during an Panel Discussion at the ALS Drug Development Summit in Boston, USA (May 16-18, 2023).

The lung cancer five-year survival rate has increased by nearly 40% in the past decade. Unfortunately, this progress has not been shared equally.

Monogram Orthopaedics Inc. announced it raised $17,216,147 through the sale of 2,374,641 shares of its Class A Common Stock priced at $7.25 per share.

Biovica announces that Biovica Inc, the US laboratory and subsidiary of Biovica International AB, has signed a provider contract with MediNcrease Health Plans, a US, national provider network and provider advocacy firm, to make Biovica’s blood test DiviTum® TKa available to the more than 15 million lives served by Clients and Payers of MediNcrease.

Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at two virtual investor conferences in May.

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) announces today that it will host its rescheduled corporate update conference call to review first quarter financial results and provide an update on corporate developments on Thursday, May 18, 2023, at 8:30am ET.